story of the week
Pembrolizumab vs Docetaxel for Previously Treated, PD-L1–Positive, Advanced Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet